Synthesis and Characterization of Magnetic Nanodrugs and Their Resistance on the Chemotherapy of Bladder Cancer

The purpose of this project is to develop a material of magnetic nanoparticles (MNPs) that could carry the drugs, such as Epirubicin, Doxorubicin and Ixabepilone, to inhibit the growth of drug-resistance bladder cancer cells. The drugs are – immobilized on the surfaces of MNPs and guided by the applied external magnet for concentration effective and targeted therapy. This is a 3-year project, which comprises the following research topics: 1. Synthesis the water solvable Fe3O4 nanoparticles with various sizes and magnetizations, and characterize their structural and physical properties. 2. Synthesis the water suspension Fe3O4/Polyaniline derivatives (Fe3O4/SPAnH and/or Fe3O4/MPAnH) core/shell nanoparticles. Drugs, such as Epirubicin, Doxorubicin and Ixabepilone, are immobilized on the surface of Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles by covalent bonding and dispersed uniformly in water. Structural and physical properties of drugs bound with Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles are characterized and correlated to their in-vitro therapy effect. 3. Activity analysis of drugs bound with Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles. 4. Cytotoxicity assay of drugs bound with Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles. 5. In vitro magnetic guiding test of drugs bound with Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles. 6. The study of mechanism that the drugs bound with Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles reverse the drug-resistance of bladder cancer cells. 7. In vivo test that the drugs bound with Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles against the cell membrane drug-resistance of bladder cancer cells. 8. In vivo test that the drugs bound with Fe3O4/SPAnH and/or Fe3O4/MPAnH nanoparticles against the cell nuclear drug-resistance of bladder cancer cells.

Project ID:PB10007-7225
External Project ID:NSC100-2221-E182-005